ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "interstitial lung disease"

  • Abstract Number: 2912 • 2016 ACR/ARHP Annual Meeting

    Performance of the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 in Systemic Sclerosis -Associated Interstitial Lung Disease (SSc-ILD)

    Caitlyn Fisher1,2, Rajaie Namas3, Amber Young2, Holly Wilhalme4 and Dinesh Khanna5, 1Cognitive Science / Creative Writing, Beloit College, Beloit, WI, 2Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, 3Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI, 4University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 5University of Michigan, Ann Arbor, MI

    Background/Purpose:  PROMIS-29 is a generic health-related quality of life (HRQoL) instrument that was developed as part of the NIH Patient Reported Outcomes (PROs) Roadmap. Our…
  • Abstract Number: 971 • 2016 ACR/ARHP Annual Meeting

    Reliability and Minimal Clinically Important Differences (MCID) of Forced Vital Capacity: Post-Hoc Analyses from the Scleroderma Lung Studies (SLS-I and II)

    Suzanne Kafaja1, Philip J. Clements2, Holly Wilhalme3, Daniel E. Furst4, Chi-hong Tseng2, Kim Hyun5, Jonathan Goldin3, Elizabeth R. Volkmann3, Michael Roth2, Donald P. Tashkin6 and Dinesh Khanna7, 1Medicine/Rheumatology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 2Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 3University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 4David Geffen School of Medicine at UCLA, Los Angeles, CA, 5Radiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, 6David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, 7University of Michigan, Ann Arbor, MI

    Background/Purpose: Forced vital capacity (FVC) is used as a primary outcome measure in clinical trials of systemic sclerosis-related interstitial lung disease (SSc-ILD). Minimally Clinically Important…
  • Abstract Number: 3249 • 2016 ACR/ARHP Annual Meeting

    Improvement in Cough and Cough-Related Quality of Life in Participants Undergoing Treatment for Systemic Sclerosis-Related Interstitial Lung Disease

    Elizabeth R. Volkmann1, Dinesh Khanna2, Chi-hong Tseng3, Robert Elashoff4, Bingling Wang5, Michael Roth3, Philip J. Clements3, Daniel E. Furst1, Arthur Theodore6 and Donald P. Tashkin7, 1University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 2University of Michigan, Ann Arbor, MI, 3Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 4Biomathematics, University of California, Los Angeles, Los Angeles, CA, 5Biostatistics, University of California, Los Angeles, Los Angeles, CA, 6Medicine, Boston University, Boston, MA, 7David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA

    Background/Purpose: While chronic cough occurs in the majority of patients with systemic sclerosis-related interstitial lung disease (SSc-ILD),1 its impact on quality of life has not…
  • Abstract Number: 1236 • 2016 ACR/ARHP Annual Meeting

    Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs

    Karina Raimundo1, Amanda Farr2, Ashley Cole3 and Jeffrey J. Swigris4, 1Genentech, Inc., a Member of the Roche Group, South San Francisco, CA, 2Truven Health Analytics, Cambridge, MA, 3Truven Health Analytics, Bethesda, MD, 4Division of Pulmonary and Critical Care Medicine, National Jewish Health, Denver, CO

    Background/Purpose: Interstitial lung disease (ILD) is commonly associated with rheumatoid arthritis (RA) and can have significant morbidity and mortality. The objective was to calculate the…
  • Abstract Number: 1456 • 2016 ACR/ARHP Annual Meeting

    Identification of a Unique Population of B220hi B-Cells in Inflamed Lymph Nodes (Bin) As a Potential Biomarker of Arthritic Progression in the Tumor Necrosis Factor Transgenic Mouse Model of Rheumatoid Arthritis

    Megan Forney1, Richard Bell2, Edward Schwarz3 and Homaira Rahimi4, 1Orthopedics, University of Rochester, Rochester, NY, 2Pathology, University of Rochester, Rochester, NY, 3Orthopedeatrics, University of Rochester, Rochester, NY, 4Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY

    Background/Purpose: Using the tumor necrosis factor transgenic (TNF-Tg) mouse model of rheumatoid arthritis (RA), we have shown that during progression of knee synovitis, popliteal lymph…
  • Abstract Number: 1501 • 2016 ACR/ARHP Annual Meeting

    The Incidence of Interstial Lung Disease and Malignancies in Veterans with Rheumatoid Arthritis

    Katherine Larson1, Faizah Siddique2 and Samya Mohammad1, 1Virginia Commonwealth University, Richmond, VA, 2Department of Veterans Affairs, Richmond, VA

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic disease with a known association with lymphoma and interstitial lung disease (ILD). ILD is a frequent extraarticular manifestation…
  • Abstract Number: 2962 • 2015 ACR/ARHP Annual Meeting

    Efficacy of Mycophenolate As a Maintenance Therapy Following the Administration of Cyclophosphamide in the Treatment of Interstitial Lung Disease Associated with Systemic Sclerosis

    Javier Narváez1, Helena Borrell Paños2, Ivan Castellvi3, Sergi Heredia2, Milena Millan3, Susana Herrera4, Eulalia Armengol2, Josep María LLobet3, Joan Miquel Nolla2, María Molina5 and Juan José Alegre6, 1Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 2Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 3Rheumatology Unit. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 4Deparment of Pneumology, Hospital Universitario Dr Peset, Valencia, Spain, 5Department of Pneumology, Hospital Universitario de Bellvitge, Barcelona, Spain, 6Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain

    Background/Purpose: Treatment with cyclophosphamide (CYC) for 12 months stabilizes lung function parameters and improves respiratory symptoms of patients with systemic sclerosis and diffuse interstitial lung…
  • Abstract Number: 288 • 2015 ACR/ARHP Annual Meeting

    Myositis Associated Interstitial Lung Disease: Clinical Predictors of Failure to Conventional Treatment and Their Response to Tacrolimus

    Niharika Sharma1, Anisha Dua1, Michael Putman2, Rekha Vij3 and Mary Strek3, 1Rheumatology, The University of Chicago, Chicago, IL, 2Internal Medicine, The University of Chicago, Chicago, IL, 3Pulmonology, The University of Chicago, Chicago, IL

    Background/Purpose: Interstitial lung disease (ILD) frequently complicates Polymyositis (PM) and Dermatomyositis (DM) and accounts for significant morbidity and mortality in affected patients.  Patients with Myositis…
  • Abstract Number: 2611 • 2015 ACR/ARHP Annual Meeting

    Circulating Monocyte Count Is Significantly Associated with Interstitial Pneumonia in Biologic-Naive Patients with Rheumatoid Arthritis: A Single-Center Prospective Cohort Study (Keio First-Bio Cohort Study)

    Keisuke Izumi1, Misato Hashizume2, Yuko Kaneko3, Keiko Yoshimoto1 and Tsutomu Takeuchi1, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 2Product Research Department, Fuji-Gotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, 3Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose : Interstitial pneumonia (IP) is one of the most critical complications in rheumatoid arthritis (RA). Severe IP is developed in zymosan-treated SKG mice, and…
  • Abstract Number: 2375 • 2015 ACR/ARHP Annual Meeting

    Interstitial Lung Disease in Patients with Anti-PM-Scl Antibody

    Hiromichi Tamaki1, Ruchi Yadav2, James Bena3 and Soumya Chatterjee4, 1Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Foundation, Cleveland, OH, 2Diagnostic Radiology, Cleveland Clinic, Cleveland, OH, 3Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, 4Cleveland Clinic Foundation, Cleveland, OH

    Background/Purpose: Patients with anti-PM-Scl antibody (PM-Scl) can present with several different phenotypes: polymyositis (PM), dermtomyositis (DM), systemic sclerosis (SSc), scleromyositis, or sclero-dermatomyositis. Interstitial Lung Disease…
  • Abstract Number: 2362 • 2015 ACR/ARHP Annual Meeting

    Rituximab in the Treatment of Jo-1 Antibody-Associated Antisynthetase Syndrome: Anti-Ro52 Positivity As a Marker for Severity and Treatment Response

    Jutta Bauhammer1, Norbert Blank2, Hanns-Martin Lorenz3, Regina Max4, Dietmar Krause5 and Christoph Fiehn1, 1ACURA Centre for Rheumatic Diseases, Baden-Baden, Germany, 2Dept. of Internal Medicine 5, Division of Rheumatology, University of Heidelberg, Heidelberg, Germany, 3Department of Internal Medicine 5, Division of Rheumatology, University of Heidelberg, Heidelberg, Germany, 4Dept. of Internal Medicine 5, Division of Rheumatology, University of Heidelberg, Heidelberg, Germany, 5Dept. of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, Germany

    Background/Purpose: Rituximab (RIX) has successfully been used for the treatment of severe Jo-1 antibody-associated antisynthetase syndrome (Jo-1 ASS). The aim of this retrospective study was…
  • Abstract Number: 2360 • 2015 ACR/ARHP Annual Meeting

    The Effectiveness of Tacrolimus in Patients with Interstitial Lung Disease Secondary to Autoimmune Disease

    Hina Chaudhry1, Rochella A. Ostrowski2 and Rodney Tehrani3, 1Rheumatolgoy, Loyola University Medical Center, Maywood, IL, 2Rheumatology, Loyola University Medical Center, Maywood, IL, 3Rheum & Immun, Loyola Univ Medical Center, Maywood, IL

    Background/Purpose: Interstitial lung disease (ILD) secondary to connective tissue disease (CTD) is most commonly seen in systemic sclerosis followed by polymyositis and dermatomyositis.  Anti-synthetase syndrome…
  • Abstract Number: 1897 • 2015 ACR/ARHP Annual Meeting

    Fragmented Qrs Patterns Do Not Correlate with the Degree of Lung and Skin Involvement in Patients with Systemic Sclerosis

    Didem Uzunaslan1, Caner Saygin1, Mehmet Kostek2, Mehmet Ozdemir2, Tufan Torun2, Servet Altay3 and Gulen Hatemi4, 1Cleveland Clinic, Cleveland, OH, 2Istanbul University, Cerrahpasa Faculty of Medicine, Istanbul, Turkey, 3Edirne Community Hospital, Edirne, Turkey, 4Rheumatology, Istanbul University, Cerrahpasa Medical School, Istanbul, Turkey

    Background/Purpose: Cardiac involvement is a common subclinical feature of systemic sclerosis (SSc) and results from the widespread fibrosis observed during disease course. Fragmented QRS (fQRS)…
  • Abstract Number: 1882 • 2015 ACR/ARHP Annual Meeting

    The Predictive Value of Pulmonary Function Tests to Diagnose Interstitial Lung Disease in Adults with Early Diffuse Cutaneous Systemic Sclerosis

    Elana J. Bernstein1, Veronica J. Berrocal2, Virginia D. Steen3, Victoria K. Shanmugam4,5, Ami A. Shah6, Monique E. Hinchcliff7, Faye N. Hant8, Jessica K. Gordon9, Tracy M. Frech10, Robyn T. Domsic11, Shervin Assassi12 and Dinesh Khanna13, 1Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, 2Div of Rheumatology, University of Michigan, Ann Arbor, MI, 3Rheumatology, Georgetown University Medical Center, Washington, DC, 4Division of Rheumatology, The George Washington University, Washington, DC, 5Director, Division of Rheumatology, The George Washington University, Washington, DC, 6Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 7Rheumatology, Northwestern University, Chicago, IL, 8Dept of Medicine, Medical University of South Carolina, Charleston, SC, 9Rheumatology, Hospital for Special Surgery, New York, NY, 10Div of Rheumatology, University of Utah, Salt Lake City, UT, 11Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, 12Rheumatology, University of Texas Medical School at Houston, Houston, TX, 13Division of Rheumatology, University of Michigan, Ann Arbor, MI

    Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). Patients with diffuse cutaneous systemic sclerosis (dcSSc) have…
  • Abstract Number: 1590 • 2015 ACR/ARHP Annual Meeting

    Rheumatoid Arthritis-Related Interstitial Lung Disease (RA-ILD): Methotrexate and the Extension of Lung Disease Are Associated to Prognosis

    Jorge Rojas-Serrano1, Denisse Herrera-Bringas2, Renzo Perez-Dorame3, Mayra Mejia2 and Heidegger Mateos-Toledo4, 1Interstitial Lung Diseases Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, 2Interstitial Lung Diseases Unit, Insituto Nacional de Enfermedades Respiratorias, Mexico, Mexico, 3Intertitial Lung Disease Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico, Mexico, 4Interstitial Lung Diseases Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico, Mexico

    Background/Purpose:Interstitial lung disease (ILD) is a severe rheumatoid arthritis manifestation with a median survival of 2.6 years. Worst survival has been associated to usual interstitial…
  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies